カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

ゲノミクスにおける人工知能（AI）の世界市場予測（～2028）：提供別、技術別、機能別、用途別、エンドユーザー別

◆英語タイトル：Artificial Intelligence In Genomics Market by Offering (Software & Services), Technology (Machine Learning), Functionality (Gene Sequencing, Gene Editing), Application (Diagnostics, Drug discovery), End User (Pharma, Hospitals) - Global Forecasts to 2028
	◆商品コード：HIT7852-23 ◆発行会社（リサーチ会社）：MarketsandMarkets ◆発行日：2023年5月11日 ◆ページ数：240 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥752,400	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥1,010,800	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,238,800	見積依頼/購入/質問フォーム

★MarketsandMarketsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

マーケッツアンドマーケッツ社では、世界のゲノミクスにおける人工知能（AI）市場規模が2023年5億ドルから2028年20億ドルまで、予測期間中、年平均32.3%成長すると予測しています。当調査資料では、ゲノミクスにおける人工知能（AI）の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、提供別（ソフトウェア、サービス）分析、技術別（機械学習、その他）分析、機能別（遺伝子シーケンス、ゲノム編集、臨床ワークフロー、予測遺伝子検査＆予防医学）分析、用途別（診断薬、創薬＆開発、精密医療、農業＆動物研究、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、その他地域）分析、競争状況、隣接/関連市場などの項目を掲載しています。なお、当書に掲載されている企業情報には、NVIDIA Corporation (US)、Microsoft Corporation (US)、Google, Inc. (US)、Intel Corporation (US)、BenevolentAI (UK)、SOPHiA GENETICS (Switzerland)、Illumina, Inc. (US)、Predictive Oncology, Inc. (US)、Invitae Corporation (US)、Deep Genomics, Inc. (Canada)、Fabric Genomics, Inc. (US)などが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のゲノミクスにおける人工知能（AI）市場規模：提供別
　 - ソフトウェアの市場規模
　 - サービスの市場規模
・世界のゲノミクスにおける人工知能（AI）市場規模：技術別
　 - 機械学習技術の市場規模
　 - その他技術の市場規模
・世界のゲノミクスにおける人工知能（AI）市場規模：機能別
　 - 遺伝子シーケンスの市場規模
　 - ゲノム編集の市場規模
　 - 臨床ワークフローの市場規模
　 - 予測遺伝子検査＆予防医学の市場規模
・世界のゲノミクスにおける人工知能（AI）市場規模：用途別
　 - 診断薬における市場規模
　 - 創薬＆開発における市場規模
　 - 精密医療における市場規模
　 - 農業＆動物研究における市場規模
　 - その他用途における市場規模
・世界のゲノミクスにおける人工知能（AI）市場規模：地域別
　 - 北米のゲノミクスにおける人工知能（AI）市場規模
　 - ヨーロッパのゲノミクスにおける人工知能（AI）市場規模
　 - アジア太平洋のゲノミクスにおける人工知能（AI）市場規模
　 - その他地域のゲノミクスにおける人工知能（AI）市場規模
・競争状況
・企業情報

“ゲノミクスにおける人工知能（AI）市場は、2023年の推定5億米ドルから2028年には20億米ドルに成長すると予測され、予測期間中の年平均成長率は32.3%になる見込み”
同市場が有望な成長ポテンシャルを持つ背景には、プロセスやタイムラインの迅速化、創薬・薬剤開発の短縮化、コンピューティングパワーの向上、ハードウェアコストの低下などがあります。しかし、キュレーションされたゲノムデータの不足やデータプライバシーに関する懸念が、この市場の成長をある程度制限すると予想されます。

“ディープラーニング：ゲノミクスにおける人工知能（AI）市場における機械学習セグメントの急成長（タイプ別）”
ディープラーニング（深層学習）セグメントは、予測期間中、感染監視サービス市場で最も成長する見込みです。ディープラーニング手法は、DNA配列からのタンパク質結合の理解、エピジェネティック修飾、エピジェネティックマークからの遺伝子発現の予測、単一細胞のメチル化状態の予測に至るまで、さまざまな問題に対処するために使用されているゲノミクスにおける計算モデリング戦略を支配しています。ゲノムシーケンス解析ワークフローの加速に対する需要の高まりと、遺伝子編集ツールの機能向上に対するニーズが、市場の成長を促進すると予想されます。

“ゲノムシーケンス分野は、予測期間中、機能別でゲノミクスにおける人工知能（AI）市場で最大シェアになると予測”
機能性に基づいて、市場はゲノムシーケンス、遺伝子編集、臨床ワークフロー、予測遺伝子検査・予防医学に区分されます。ゲノミクスにおける人工知能（AI）市場で最大のシェアを占めるのはゲノムシーケンス分野です。このセグメントの大きなシェアは、染色体異常、異形症候群、催奇形性疾患、単一遺伝子疾患を特定するためのAIソリューションの使用に起因しています。

“予測期間中、ゲノミクスにおける人工知能（AI）市場で欧州が第2位のシェアを占める”
予測期間中、ゲノミクスにおける人工知能（AI）市場では欧州が第2位のシェアを占めました。市場成長の主な促進要因は、ゲノム研究および創薬におけるAIベースのツール採用の増加、有利な政府イニシアティブ、EMR採用の増加、患者データ量の増加、ベンチャーキャピタルからの資金調達の増加、医療支出の増加、老人人口の増加などです。さらに、研究開発活動の推進におけるAIの可能性も、この分野に注目を集めています。

主な参加企業の内訳は以下の通り：
– 企業タイプ別 – ティア1-40%、ティア2-35%、ティア3-25%
– 役職別 – Cレベル-35%、ディレクターレベル-25%、その他-40%
– 地域別 – 北米-45%、欧州-30%、アジア太平洋地域-20%、その他-5%

ゲノミクスにおける人工知能（AI）市場の主要企業
ゲノミクスにおける人工知能（AI）市場で事業を展開する主なプレーヤーには、NVIDIA Corporation（米国）、Microsoft Corporation（米国）、Google, Inc.（米国）、Intel Corporation（米国）、BenevolentAI（英国）、SOPHiA GENETICS（スイス）、Illumina, Inc.（米国）、Predictive Oncology, Inc.（米国）、Invitae Corporation（米国）、Deep Genomics, Inc.（カナダ）、Fabric Genomics, Inc. (米国）、Verge Genomics社（米国）、Freenome Holdings社（米国）、MolecularMatch社（米国）、Dante labs社（米国）、Data4Cure社（米国）、PrecisionLife Ltd社（英国）、Genoox社（米国）、Lifebit社（英国）、FDNA, Inc. (米国）、DNAnexus社（米国）、Engine Biosciences社（米国）、Tempus Labs社（米国）、Congenica Ltd社（英国）、Emedgene社（米国）、Seragon Pharmaceuticals社（米国）などが含まれます。

調査範囲
当レポートでは、ゲノミクスにおける人工知能（AI）市場を分析し、提供、技術、機能、用途、エンドユーザー、地域などの様々なセグメントに基づいて、市場規模や今後の成長可能性を推定することを目的としています。また、市場で入手可能な様々なゲノミクスにおける人工知能（AI）製品＆サービスの製品ポートフォリオマトリックスも掲載しています。また、同市場における主要企業の競合分析も行っており、企業プロフィール、提供製品、主要市場戦略も掲載しています。

レポート購入の理由
本レポートは、既存企業だけでなく、新規参入企業や小規模企業も市場の動向を把握するのに役立ちます。本レポートを購入された企業は、以下の戦略のいずれか、または任意の組み合わせを使用して、市場での地位を強化することができます。

本レポートでは、以下の点について考察しています：
– 市場参入：世界のゲノミクスにおける人工知能（AI）市場のトップ企業が提供する製品ポートフォリオに関する包括的な情報。製品・サービス別、エンドユーザー別に市場を分析。
– 製品の強化/革新：ゲノミクスにおける人工知能（AI）の世界市場における今後の動向と製品発売に関する詳細な洞察。
– 市場開発：製品・サービス別、エンドユーザー別の有利な新興市場に関する包括的情報。
– 市場の多様化：ゲノミクスにおける人工知能（AI）の世界市場における新製品や製品強化、成長地域、最近の開発、投資に関する詳細情報。
– 競合評価：世界のゲノミクスにおける人工知能（AI）市場における主要企業の市場シェア、成長戦略、製品提供、競争上のリーダーシップマッピング、能力に関する詳細な評価。

❖ レポートの目次 ❖

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.3 INCLUSIONS AND EXCLUSIONS 33
1.4 STUDY SCOPE 34
1.4.1 MARKETS COVERED 34
FIGURE 1 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SEGMENTATION 34
1.4.2 REGIONS COVERED 34
1.5 YEARS CONSIDERED 35
1.6 CURRENCY CONSIDERED 36
TABLE 1 CURRENCY CONVERSION RATES 36
1.7 LIMITATIONS 36
1.8 STAKEHOLDERS 37
1.9 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
FIGURE 2 RESEARCH DESIGN 40
FIGURE 3 RESEARCH APPROACH 41
2.1.1 SECONDARY RESEARCH 42
2.1.1.1 Key data from secondary sources 43
2.1.2 PRIMARY RESEARCH 43
2.1.2.1 Key primary sources 44
2.1.2.2 Key data from primary sources 45
2.1.2.3 Key industry insights 45
2.1.2.4 Breakdown of primary interviews 46
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 46
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 46
2.2 MARKET SIZE ESTIMATION 46
FIGURE 6 KEY METRICS FOR ASSESSING SUPPLY OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET 47
FIGURE 7 REVENUES GENERATED BY COMPANIES FROM SALE OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS SOLUTIONS 48
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION 49
FIGURE 9 BOTTOM-UP APPROACH 50
FIGURE 10 ESTIMATION OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SIZE BASED ON ADOPTION 50
FIGURE 11 TOP-DOWN APPROACH 51
TABLE 2 FACTOR ANALYSIS 52
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 52
FIGURE 12 DATA TRIANGULATION METHODOLOGY 53
2.4 RESEARCH ASSUMPTIONS 54
FIGURE 13 ASSUMPTIONS FOR RESEARCH STUDY 54
2.5 IMPACT OF RECESSION 55
2.6 RISK ASSESSMENT 55
TABLE 3 LIMITATIONS AND ASSOCIATED RISKS 55
2.7 RESEARCH LIMITATIONS 56
3 EXECUTIVE SUMMARY 57
FIGURE 14 SOFTWARE SEGMENT TO LEAD ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING 57
FIGURE 15 MACHINE LEARNING CONTINUES TO ACQUIRE LARGEST SIZE OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY 58
FIGURE 16 DEEP LEARNING TO BE FASTEST-GROWING SEGMENT OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING 58
FIGURE 17 GENOME SEQUENCING TO REGISTER HIGHEST CAGR IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY 59
FIGURE 18 DIAGNOSTICS TO DOMINATE ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION 60
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO SECURE LEADING POSITION IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER 60
FIGURE 20 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION 61
4 PREMIUM INSIGHTS 62
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET 62
FIGURE 21 INCREASING ADOPTION OF ARTIFICIAL INTELLIGENCE (AI) SOLUTIONS FOR DRUG DISCOVERY & DEVELOPMENT AND PRECISION MEDICINE TO DRIVE MARKET 62
4.2 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION 63
FIGURE 22 NORTH AMERICA TO DOMINATE ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET DURING FORECAST PERIOD 63
4.3 NORTH AMERICAN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER AND COUNTRY, 2022 64
FIGURE 23 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US DOMINATED MARKET IN NORTH AMERICA IN 2022 64
4.4 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING 65
FIGURE 24 SOFTWARE SEGMENT TO HOLD MAJORITY MARKET SHARE IN 2028 65
4.5 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY 65
FIGURE 25 MACHINE LEARNING TO SURPASS OTHER TECHNOLOGIES IN 2028 65
4.6 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER 66
FIGURE 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2028 66
4.7 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY 66
FIGURE 27 GENOME SEQUENCING TO BE FASTEST-GROWING SEGMENT DURING FORECAST PERIOD 66
4.8 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION 67
FIGURE 28 DIAGNOSTICS TO DOMINATE MARKET IN 2028 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
5.2.1 DRIVERS 69
5.2.1.1 Need to accelerate processes and timeline and reduce drug development & discovery costs 69
5.2.1.2 Increased partnerships and collaborations among players and growing investments in AI in genomics 69
5.2.1.3 Rising adoption of AI in precision medicine 70
5.2.1.4 Explosion in bioinformatics data and genomic datasets 70
FIGURE 29 COST OF GENOME ANALYSIS VS. LEVELS OF RAW DATA GENERATED, 2003–2023 71
5.2.1.5 Improving computing power and declining hardware cost 71
5.2.2 RESTRAINTS 72
5.2.2.1 Lack of skilled AI workforce and ambiguous regulatory guidelines for medical software 72
5.2.3 OPPORTUNITIES 72
5.2.3.1 Focus on developing human-aware AI systems 72
5.2.4 CHALLENGES 73
5.2.4.1 Lack of curated genomic data 73
5.2.4.2 Data privacy concerns 73
FIGURE 30 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2019–2021 73
5.3 ECOSYSTEM ANALYSIS 74
FIGURE 31 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: ECOSYSTEM ANALYSIS 74
6 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING 75
6.1 INTRODUCTION 76
FIGURE 32 SOFTWARE SEGMENT ACCOUNTED FOR LARGER MARKET SHARE IN 2022 76
TABLE 4 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 76
6.2 SOFTWARE 77
6.2.1 INTELLIGENT SOFTWARE TO REDUCE ERRORS CAUSED BY STANDARD STATISTICAL APPROACHES 77
TABLE 5 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 77
TABLE 6 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 7 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 78
6.3 SERVICES 78
6.3.1 RISING AI TECHNOLOGY ADOPTION IN VARIOUS END-USE INDUSTRIES TO BOOST MARKET 78
TABLE 8 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 79
TABLE 9 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 10 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 79
7 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY 80
7.1 INTRODUCTION 81
FIGURE 33 MACHINE LEARNING SEGMENT ACCOUNTED FOR LARGER MARKET SHARE IN 2022 81
TABLE 11 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 81
7.2 MACHINE LEARNING 82
FIGURE 34 DEEP LEARNING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 82
TABLE 12 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TYPE, 2021–2028 (USD MILLION) 83
TABLE 13 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 14 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 15 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 84
7.2.1 DEEP LEARNING 84
7.2.1.1 Growing demand for accelerated genome sequencing analysis workflows and improved function of gene editing tools to propel market 84
TABLE 16 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 85
TABLE 17 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 18 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 85
7.2.2 SUPERVISED LEARNING 86
7.2.2.1 To help create predictive models for population health management 86
TABLE 19 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 86
TABLE 20 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 21 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 87
7.2.3 REINFORCEMENT LEARNING 87
7.2.3.1 Need to reduce costs associated with collecting labeled training data to drive segment 87
TABLE 22 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 23 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 24 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 88
7.2.4 UNSUPERVISED LEARNING 89
7.2.4.1 Ability to perform more complex processing tasks than supervised learning systems to drive market 89
TABLE 25 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 26 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 27 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 90
7.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 90
TABLE 28 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 90
TABLE 29 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 30 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 91
7.3 OTHER TECHNOLOGIES 91
TABLE 31 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 92
TABLE 32 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 33 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 92
8 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY 93
8.1 INTRODUCTION 94
FIGURE 35 GENOME SEQUENCING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 94
TABLE 34 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 94
8.2 GENOME SEQUENCING 95
8.2.1 INCREASING ADOPTION OF MACHINE AND DEEP LEARNING IN DIAGNOSTICS AND DRUG DISCOVERY PROCESSES TO ENHANCE MARKET GROWTH 95
TABLE 35 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 95
TABLE 36 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 37 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 96
8.3 GENE EDITING 96
8.3.1 TO HELP IMPROVE GENE EDITING FUNCTIONS AND REDUCE TIME AND COSTS 96
TABLE 38 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 39 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 40 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 98
8.4 CLINICAL WORKFLOW 98
8.4.1 TO HELP INCREASE EFFICIENCY OF CLINICAL WORKFLOWS 98
TABLE 41 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 42 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 43 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 99
8.5 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE 99
8.5.1 AI IN GENOMICS TO PREDICT OUTCOMES AND RISKS ASSOCIATED WITH CURING GENETIC DISEASES BASED ON AVAILABLE DATA 99
TABLE 44 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 45 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 46 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 100
9 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION 101
9.1 INTRODUCTION 102
FIGURE 36 DIAGNOSTICS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 102
TABLE 47 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 102
9.2 DIAGNOSTICS 103
9.2.1 AI IN GENOMICS FOR DIAGNOSTICS TO HELP IDENTIFY CHROMOSOMAL DISORDERS, DYSMORPHIC SYNDROMES, TERATOGENIC DISORDERS, AND SINGLE-GENE DISORDERS 103
TABLE 48 INDICATIVE LIST OF DEVELOPMENTS FOR DIAGNOSTICS APPLICATION 104
TABLE 49 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 50 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 51 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 105
9.3 DRUG DISCOVERY & DEVELOPMENT 105
9.3.1 GROWING APPLICATION OF AI IN GENOMICS IN DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET 105
TABLE 52 INDICATIVE LIST OF DEVELOPMENTS FOR DRUG DELIVERY & DISCOVERY APPLICATION 106
TABLE 53 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 54 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 55 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 107
9.4 PRECISION MEDICINE 107
9.4.1 FOCUSE ON IDENTIFYING EFFECTIVE MEDICAL TREATMENTS FOR PATIENTS TO DRIVE MARKET 107
TABLE 56 INDICATIVE LIST OF DEVELOPMENTS FOR PRECISION MEDICINE APPLICATION 108
TABLE 57 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 58 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 59 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 109
9.5 AGRICULTURE & ANIMAL RESEARCH 109
9.5.1 AI IN GENOMICS TO HELP IMPROVE CROP AND LIVESTOCK PRODUCTIVITY 109
TABLE 60 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 110
TABLE 61 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 62 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 111
9.6 OTHER APPLICATIONS 111
TABLE 63 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 64 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 65 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 112
10 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER 113
10.1 INTRODUCTION 114
FIGURE 37 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 114
TABLE 66 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 114
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 115
10.2.1 RISING DEMAND FOR SOLUTIONS TO REDUCE TIME AND COSTS OF DRUG DEVELOPMENT 115
TABLE 67 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: INDICATIVE DEVELOPMENTS 115
TABLE 68 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 69 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 70 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 116
10.3 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS 117
10.3.1 INCREASED RESEARCH ACTIVITIES TO ENCOURAGE USE OF AI IN GENOMICS IN ACADEMIC AND GOVERNMENT INSTITUTES 117
TABLE 71 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: INDICATIVE DEVELOPMENTS 117
TABLE 72 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 73 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 74 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 118
10.4 HOSPITALS & HEALTHCARE PROVIDERS 118
10.4.1 GROWING DEMAND FOR PHARMACOGENOMICS TO PROPEL ACCEPTANCE OF NGS IN HOSPITALS 118
TABLE 75 HOSPITALS & HEALTHCARE PROVIDERS: INDICATIVE DEVELOPMENTS 119
TABLE 76 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 119
TABLE 77 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 78 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 120
10.5 OTHER END USERS 120
TABLE 79 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 80 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 81 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 121
11 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION 122
11.1 INTRODUCTION 123
FIGURE 38 ASIA PACIFIC TO EMERGE AS NEW HOTSPOT DURING FORECAST PERIOD 123
FIGURE 39 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 123
TABLE 82 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 124
11.2 NORTH AMERICA 124
11.2.1 NORTH AMERICA: RECESSION IMPACT 124
FIGURE 40 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SNAPSHOT 125
TABLE 83 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 84 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 126
TABLE 85 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126
TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 127
TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 128
TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 128
11.2.2 US 128
11.2.2.1 Initiatives to accelerate genomic research and growing adoption of AI to bolster market 128
TABLE 90 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 130
TABLE 91 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 130
TABLE 92 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 93 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 131
TABLE 94 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 131
TABLE 95 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 132
11.2.3 CANADA 132
11.2.3.1 Increasing research in genomics to drive market 132
TABLE 96 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 133
TABLE 97 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 133
TABLE 98 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 134
TABLE 100 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 134
TABLE 101 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 135
11.3 EUROPE 135
11.3.1 EUROPE: RECESSION IMPACT 135
TABLE 102 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 103 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 136
TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 137
TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 137
TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 138
TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 138
11.3.2 UK 138
11.3.2.1 Adoption of AI in genomics for drug discovery to fuel market 138
TABLE 109 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 140
TABLE 110 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140
TABLE 111 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 112 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 141
TABLE 113 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 141
TABLE 114 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 142
11.3.3 GERMANY 142
11.3.3.1 Availability of funding for AI initiatives to boost market 142
TABLE 115 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 143
TABLE 116 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143
TABLE 117 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 118 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 144
TABLE 119 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144
TABLE 120 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 145
11.3.4 FRANCE 145
11.3.4.1 Increasing government investments in NGS to boost market 145
TABLE 121 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 146
TABLE 122 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146
TABLE 123 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 124 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 147
TABLE 125 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 147
TABLE 126 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 148
11.3.5 REST OF EUROPE 148
TABLE 127 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 149
TABLE 128 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 149
TABLE 129 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 130 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 150
TABLE 131 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150
TABLE 132 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 151
11.4 ASIA PACIFIC 151
11.4.1 ASIA PACIFIC: RECESSION IMPACT 152
FIGURE 41 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SNAPSHOT 153
TABLE 133 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 154
TABLE 134 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 154
TABLE 135 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 136 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 155
TABLE 137 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155
TABLE 138 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 156
11.5 REST OF THE WORLD 156
11.5.1 REST OF THE WORLD: RECESSION IMPACT 157
TABLE 139 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 158
TABLE 140 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 158
TABLE 141 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 142 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION) 159
TABLE 143 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 159
TABLE 144 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 160
12 COMPETITIVE LANDSCAPE 161
12.1 OVERVIEW 161
12.2 KEY MARKET PLAYERS’ STRATEGIES/RIGHT TO WIN 161
TABLE 145 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET 161
FIGURE 42 KEY DEVELOPMENTS BY MAJOR MARKET PLAYERS BETWEEN JANUARY 2020 AND MARCH 2023 163
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS, 2022 164
FIGURE 43 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS, 2022 164
12.4 MARKET RANKING ANALYSIS, 2022 164
FIGURE 44 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SHARE ANALYSIS, 2022 165
12.5 COMPETITIVE BENCHMARKING 167
TABLE 146 COMPANY FOOTPRINT ANALYSIS 167
TABLE 147 PRODUCT FOOTPRINT ANALYSIS (26 COMPANIES) 168
TABLE 148 FUNCTIONALITY FOOTPRINT ANALYSIS (26 COMPANIES) 169
TABLE 149 REGIONAL FOOTPRINT ANALYSIS (26 COMPANIES) 170
12.6 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS 171
12.6.1 STARS 171
12.6.2 PERVASIVE PLAYERS 171
12.6.3 EMERGING LEADERS 171
12.6.4 PARTICIPANTS 171
FIGURE 45 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022 172
12.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES 173
12.7.1 PROGRESSIVE COMPANIES 173
12.7.2 DYNAMIC COMPANIES 173
12.7.3 RESPONSIVE COMPANIES 173
12.7.4 STARTING BLOCKS 173
FIGURE 46 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022 174
12.8 COMPETITIVE SCENARIOS AND TRENDS 175
12.8.1 PRODUCT LAUNCHES/ENHANCEMENTS 175
TABLE 150 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: PRODUCT LAUNCHES/ENHANCEMENTS, 2020–2023 175
12.8.2 DEALS 176
TABLE 151 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: DEALS, 2020–2023 176
12.8.3 OTHER DEVELOPMENTS 178
TABLE 152 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: OTHER DEVELOPMENTS, 2020–2023 178

13 COMPANY PROFILES 179
13.1 KEY PLAYERS 179
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 NVIDIA CORPORATION 179
TABLE 153 NVIDIA CORPORATION: COMPANY OVERVIEW 179
FIGURE 47 NVIDIA CORPORATION: COMPANY SNAPSHOT 180
TABLE 154 NVIDIA CORPORATION: PRODUCTS/SERVICES OFFERED 180
TABLE 155 NVIDIA CORPORATION: PRODUCT LAUNCHES/ENHANCEMENTS 181
TABLE 156 NVIDIA CORPORATION: DEALS 182
13.1.2 MICROSOFT CORPORATION 184
TABLE 157 MICROSOFT CORPORATION: COMPANY OVERVIEW 184
FIGURE 48 MICROSOFT CORPORATION: COMPANY SNAPSHOT 185
TABLE 158 MICROSOFT CORPORATION: PRODUCTS/SERVICES OFFERED 186
TABLE 159 MICROSOFT CORPORATION: DEALS 186
13.1.3 GOOGLE, INC. 189
TABLE 160 GOOGLE, INC.: COMPANY OVERVIEW 189
FIGURE 49 GOOGLE, INC.: COMPANY SNAPSHOT, 2022 190
TABLE 161 GOOGLE, INC.: PRODUCTS/SERVICES OFFERED 190
TABLE 162 GOOGLE, INC.: PRODUCT LAUNCHES/ENHANCEMENTS 191
TABLE 163 GOOGLE, INC.: DEALS 191
13.1.4 INTEL CORPORATION 193
TABLE 164 INTEL CORPORATION: COMPANY OVERVIEW 193
FIGURE 50 INTEL CORPORATION: COMPANY SNAPSHOT 194
TABLE 165 INTEL CORPORATION: PRODUCTS/SERVICES OFFERED 194
TABLE 166 INTEL CORPORATION: PRODUCT LAUNCHES/ENHANCEMENTS 195
TABLE 167 INTEL CORPORATION: DEALS 196
13.1.5 BENEVOLENTAI 198
TABLE 168 BENEVOLENTAI: COMPANY OVERVIEW 198
FIGURE 51 BENEVOLENTAI: COMPANY SNAPSHOT 198
TABLE 169 BENEVOLENTAI: PRODUCTS/SERVICES OFFERED 199
TABLE 170 BENEVOLENTAI: DEALS 199
13.1.6 SOPHIA GENETICS 201
TABLE 171 SOPHIA GENETICS: COMPANY OVERVIEW 201
FIGURE 52 SOPHIA GENETICS: COMPANY SNAPSHOT 202
TABLE 172 SOPHIA GENETICS: PRODUCTS/SERVICES OFFERED 202
TABLE 173 SOPHIA GENOMICS: DEALS 203
TABLE 174 SOPHIA GENETICS: OTHERS 204
13.1.7 ILLUMINA, INC. 205
TABLE 175 ILLUMINA, INC.: COMPANY OVERVIEW 205
FIGURE 53 ILLUMINA, INC.: COMPANY SNAPSHOT 206
TABLE 176 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 206
TABLE 177 ILLUMINA, INC.: PRODUCT LAUNCHES/ENHANCEMENTS 207
TABLE 178 ILLUMINA, INC.: DEALS 208
13.1.8 PREDICTIVE ONCOLOGY, INC. 210
TABLE 179 PREDICTIVE ONCOLOGY, INC.: COMPANY OVERVIEW 210
FIGURE 54 PREDICTIVE ONCOLOGY, INC.: COMPANY SNAPSHOT 210
TABLE 180 PREDICTIVE ONCOLOGY, INC.: PRODUCTS/SERVICES OFFERED 211
TABLE 181 PREDICTIVE ONCOLOGY, INC.: DEALS 211
13.1.9 INVITAE CORPORATION 213
TABLE 182 INVITAE CORPORATION: COMPANY OVERVIEW 213
FIGURE 55 INVITAE CORPORATION: COMPANY SNAPSHOT, 2022 214
TABLE 183 INVITAE CORPORATION: PRODUCTS/SERVICES OFFERED 214
13.1.10 DEEP GENOMICS, INC. 216
TABLE 184 DEEP GENOMICS, INC.: COMPANY OVERVIEW 216
TABLE 185 DEEP GENOMICS, INC.: PRODUCTS/SERVICES OFFERED 216
TABLE 186 DEEP GENOMICS, INC.: DEALS 217
TABLE 187 DEEP GENOMICS, INC.: OTHERS 217
13.1.11 FABRIC GENOMICS, INC. 218
TABLE 188 FABRIC GENOMICS, INC.: COMPANY OVERVIEW 218
TABLE 189 FABRIC GENOMICS, INC.: PRODUCTS/SERVICES OFFERED 218
TABLE 190 FABRIC GENOMICS, INC.: PRODUCT LAUNCHES/ENHANCEMENTS 219
TABLE 191 FABRIC GENOMICS, INC.: DEALS 219
13.1.12 VERGE GENOMICS 220
TABLE 192 VERGE GENOMICS: COMPANY OVERVIEW 220
TABLE 193 VERGE GENOMICS: PRODUCTS/SERVICES OFFERED 220
TABLE 194 VERGE GENOMICS: DEALS 221
13.1.13 FREENOME HOLDINGS, INC. 222
TABLE 195 FREENOME HOLDINGS, INC.: COMPANY OVERVIEW 222
TABLE 196 FREENOME HOLDINGS, INC.: PRODUCTS/SERVICES OFFERED 222
TABLE 197 FREENOME HOLDINGS, INC.: DEALS 223
13.1.14 MOLECULARMATCH, INC. 224
TABLE 198 MOLECULARMATCH, INC.: COMPANY OVERVIEW 224
TABLE 199 MOLECULARMATCH, INC.: PRODUCTS/SERVICES OFFERED 224
13.1.15 DANTE LABS 225
TABLE 200 DANTE LABS: COMPANY OVERVIEW 225
TABLE 201 DANTE LABS: PRODUCTS/SERVICES OFFERED 225
TABLE 202 DANTE LABS: PRODUCT LAUNCHES/ENHANCEMENTS 226
TABLE 203 DANTE LABS: DEALS 226
13.1.16 DATA4CURE 228
TABLE 204 DATA4CURE: COMPANY OVERVIEW 228
TABLE 205 DATA4CURE: PRODUCTS/SERVICES OFFERED 228
13.1.17 PRECISIONLIFE LTD 229
TABLE 206 PRECISIONLIFE LTD: COMPANY OVERVIEW 229
TABLE 207 PRECISIONLIFE LTD: PRODUCTS/SERVICES OFFERED 229
TABLE 208 PRECISIONLIFE LTD: DEALS 230
13.1.18 GENOOX 231
TABLE 209 GENOOX: COMPANY OVERVIEW 231
TABLE 210 GENOOX: PRODUCTS/SERVICES OFFERED 231
TABLE 211 GENOOX: DEALS 232
13.1.19 LIFEBIT 233
TABLE 212 LIFEBIT: COMPANY OVERVIEW 233
TABLE 213 LIFEBIT: PRODUCTS/SERVICES OFFERED 233
TABLE 214 LIFEBIT: DEALS 234
TABLE 215 LIFEBIT: OTHERS 235
13.2 OTHER EMERGING PLAYERS 236
13.2.1 FDNA, INC. 236
13.2.2 DNANEXUS 236
13.2.3 ENGINE BIOSCIENCES 237
13.2.4 TEMPUS LABS, INC. 237
13.2.5 CONGENICA LTD 238
13.2.6 EMEDGENE, INC. 238
13.2.7 SERAGON PHARMACEUTICALS, INC. 239
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 240
14.1 DISCUSSION GUIDE 240
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 245
14.3 CUSTOMIZATION OPTIONS 247
14.4 RELATED REPORTS 248
14.5 AUTHOR DETAILS 249

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ゲノミクスにおける人工知能（AI）の世界市場予測（～2028）：提供別、技術別、機能別、用途別、エンドユーザー別(Artificial Intelligence In Genomics Market by Offering (Software & Services), Technology (Machine Learning), Functionality (Gene Sequencing, Gene Editing), Application (Diagnostics, Drug discovery), End User (Pharma, Hospitals) - Global Forecasts to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

ゲノミクスにおける人工知能（AI）の世界市場予測（～2028）：提供別、技術別、機能別、用途別、エンドユーザー別

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp